Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04365985

Organisation Name: William Beaumont Hospitals

Overal Status: Recruiting

Start Date: April 29, 2020

Last Update: July 2, 2020

Lead Sponsor: William Beaumont Hospitals

Brief Summary: Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available in quantities sufficient to treat large numbers of infected people. Low doses of Naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as Ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms and prove an effective new treatment. This study will investigate their effectiveness in a randomized, blinded trial versus standard treatment plus placebo.

Conditions:
  • COVID-19
  • Acute Respiratory Distress Syndrome
  • Severe Acute Respiratory Syndrome (SARS)
  • Coronavirus Infections


Total execution time in seconds: 0.21029710769653